| 1 |
28630385 | Low Dose of Lenalidomide Enhances NK Cell Activity: Possible Implication as an Adjuvant. | 2017 Jun |
1 |
| 2 |
24351336 | Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. | 2014 Mar 1 |
2 |
| 3 |
24244261 | Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. | 2013 |
2 |
| 4 |
24244687 | Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. | 2013 |
1 |